Shouping Xu | Biology and Life Sciences | Best Researcher Award

Published on by Research Hypothesis

Assoc. Prof. Dr. Shouping Xu | Biology and Life Sciences | Best Researcher Award

Assoc. Prof. Dr. Shouping Xu | Biology and Life Sciences | Medical Physicist | Cancer Hospital Chinese Academy of Medical Sciences | China

Assoc. Prof. Dr. Shouping Xu is a distinguished medical physicist specializing in radiation oncology, with extensive expertise in advanced radiotherapy techniques and the integration of artificial intelligence in cancer treatment. He holds degrees in nuclear physics and medical physics from leading Chinese institutions and has served in senior leadership roles as Chief Clinical Medical Physicist at the Cancer Hospital, Chinese Academy of Medical Sciences, and previously at the Chinese PLA General Hospital and Yi Zhou Proton Therapy Center. Assoc. Prof. Dr. Shouping Xu  has made significant contributions to the development of innovative dose prediction models, proton therapy planning, and image-guided radiotherapy, with numerous publications in high-impact international journals. His active engagement in global conferences, memberships in professional societies, and certifications from recognized boards reflect his commitment to advancing medical physics. Widely respected for both his clinical leadership and research excellence, Assoc. Prof. Dr. Shouping Xu continues to play a key role in shaping the future of precision radiotherapy and medical imaging technologies.

Professional Profile 

Education  

Assoc. Prof. Dr. Shouping Xu has a strong academic background in physics and medical physics, beginning with a Bachelor of Science degree in Nuclear Physics Technology from Lanzhou University, China. He went on to pursue advanced studies at Tsinghua University, where he earned a Master of Science degree in Medical Physics from the Department of Engineering Physics, followed by a Doctor of Philosophy in Medical Physics from the same department. His education provided a solid foundation in radiation physics, imaging, and advanced treatment technologies, which has been central to his career in radiation oncology and his contributions to clinical innovation and research in medical physics.

Professional Experience

Assoc. Prof. Dr. Shouping Xu has built an extensive professional career in medical physics, holding key clinical and leadership positions in some of China’s most renowned cancer treatment centers. He currently serves as Chief Clinical Medical Physicist at the Proton Center of the Cancer Hospital, Chinese Academy of Medical Sciences, where he oversees clinical operations, quality management, and research in advanced radiotherapy. Previously, he was Chief Medical Physicist and Vice Director at the Yi Zhou Proton Therapy Center, where he played a pivotal role in establishing clinical workflows and implementing cutting-edge proton and photon therapies. Earlier in his career, he served at the Chinese PLA General Hospital as Chief and Senior Medical Physicist, contributing to innovations in IMRT, image-guided radiotherapy, and quality assurance. With responsibilities ranging from managing multidisciplinary teams to developing clinical protocols and engaging in pioneering research, Assoc. Prof. Dr. Shouping Xu has consistently demonstrated leadership, technical expertise, and a strong commitment to advancing radiation oncology practices.

Research Interest

Assoc. Prof. Dr. Shouping Xu’s research interests lie at the intersection of medical physics, radiation oncology, and artificial intelligence, with a focus on advancing precision radiotherapy. His work emphasizes the development of AI-driven algorithms and deep learning models for dose prediction, treatment planning, and image-guided radiotherapy, aiming to improve both the efficiency and accuracy of cancer treatment. He has conducted extensive studies on proton therapy, CyberKnife radiosurgery, and advanced techniques such as VMAT, IMRT, and adaptive radiotherapy, contributing to innovations in treatment optimization and quality assurance. Additionally, his research explores deformable image registration, dose verification, and the clinical application of AI for enhancing radiotherapy workflows. By bridging physics, engineering, and oncology, Assoc. Prof. Dr. Shouping Xu is committed to translating cutting-edge technologies into practical clinical tools that improve outcomes and safety for cancer patients.

Award and Honor

Assoc. Prof. Dr. Shouping Xu has earned recognition for his significant contributions to medical physics and radiation oncology through his active involvement in international conferences, professional societies, and research achievements. He has been an invited speaker and presenter at prestigious forums such as the AAPM Annual Meetings, the IUPESM World Congress on Medical Physics and Biomedical Engineering, and the Asia-Oceania Congress of Medical Physics, where his work on advanced radiotherapy techniques and AI-driven innovations has been highlighted. His leadership roles as Chief Clinical Medical Physicist and his certifications from the Chinese Board of Medical Physicists (CBMP) and the Chinese Board of Radiation Protection (CBRP) further underscore his professional excellence. Through his research, publications, and professional service, Assoc. Prof. Dr. Shouping Xu has gained both national and international recognition, reflecting his status as a highly respected figure in the field of medical physics.

Publications Top Noted

Dosimetric evaluation of intensity modulated proton therapy and photon volumetric modulated arc therapy for bilateral breast cancer
Year: 2025

Virtual-simulation boosted neural network dose calculation engine for intensity-modulated radiation therapy
Year: 2025

Dose rate correction of a diode array for universal wedge field dosimetric verification
Year: 2025

gMCAP: a GPU-based Monte Carlo proton transport program for high-density tissues with precise nuclear reaction models
Year: 2025

An AI dose-influence matrix engine for robust pencil beam scanning protons therapy
Year: 2025

A feasibility study of dose-band prediction in radiation therapy: Predicting a spectrum of plan dose
Year: 2025

A StarGAN and transformer-based hybrid classification-regression model for multi-institution VMAT patient-specific quality assurance
Year: 2025

Dose prediction of CyberKnife Monte Carlo plan for lung cancer patients based on deep learning: robust learning of variable beam configurations
Year: 2024

Dosimetric comparison of ZAP-X, Gamma Knife, and CyberKnife stereotactic radiosurgery for single brain metastasis
Year: 2024

Conclusion

Assoc. Prof. Dr. Shouping Xu is highly suitable for the Best Researcher Award. His combination of clinical leadership, innovative research in AI-driven radiation therapy, and active participation in international scientific forums positions him as a thought leader in medical physics and oncology. With his strong portfolio of publications and pioneering approaches to radiation therapy planning and quality assurance, he demonstrates both scientific excellence and clinical relevance. With further emphasis on international collaborations and translational outcomes, his contributions will continue to shape the future of precision radiotherapy.

Mohamed Houta | Biology and Life Sciences | Best Researcher Award

Published on by Research Hypothesis

Mohamed Houta | Biology and Life Sciences | Best Researcher Award

Mr Mohamed Houta, Beni Suef University, Egypt

Mohamed Houta appears to be a strong candidate for the Research for Best Researcher Award based on his extensive experience and contributions in the field of vaccinology, particularly related to poultry diseases

publication profile

google scholar

Solid Background in Immunology and Vaccinology

Mohamed has a robust foundation in immunology and vaccine research, which is evident from his current role as a Scientific Affairs Manager at Klybeck Life Sciences and his prior experience at MEVAC for Vaccines. His focus on inactivated and live poultry vaccines, conducting preclinical and clinical trials, and ensuring regulatory compliance underscores his deep expertise.

Significant Research Contributions

His publication record highlights his research impact. For example, his work on the Emergence, Evolution, and Spread of Infectious Bronchitis Virus Genotype GI-23 published in Archives of Virology and Phylodynamic and Recombination Analyses published in Animals demonstrate his ability to conduct significant and relevant research. These studies have contributed to a better understanding of avian diseases, which is critical for advancing vaccine development.

Leadership in R&D

As a Scientific Affairs Manager, Mohamed has demonstrated leadership in research and development, particularly in vaccine design and production, including the implementation of complex R&D projects and ensuring compliance with European and Saudi regulations. His involvement in reviewing and approving the development and validation of analytical methods and in vivo vaccine testing protocols indicates a strong leadership role in research.

Ongoing Academic Pursuits

Mohamed is also pursuing a PhD in Veterinary Sciences with a focus on poultry diseases at Beni Suef University and Padua University, which further strengthens his qualifications as a researcher committed to advancing knowledge in his field.

Global Perspective

His involvement in research and clinical trials across different countries and his multilingual abilities (Arabic, English, and Italian) add a global perspective to his work, which is valuable in the context of a global award.

Conclusion

Given Mohamed Houta’s extensive research contributions, leadership in R&D, and ongoing academic pursuits, he is a suitable candidate for the Research for Best Researcher Award. His work not only advances public health through vaccine development but also contributes significantly to the global understanding of avian diseases.

Publication top notes

The emergence, evolution and spread of infectious bronchitis virus genotype GI-23

Phylodynamic and recombination analyses of avian infectious bronchitis GI-23 reveal a widespread recombinant cluster and new among-countries linkages

COVID-19: Risk assessment and mitigation measures in healthcare and non-healthcare workplaces

Infection with Avian Coronaviruses: A recurring problem in turkeys

Dall’Est all’Ovest: ricostruzione filodinamica della storia della variante 2 del virus della bronchite infettiva aviare

 

 

Andrei Kozlov | Evolutionary Biology | Best Researcher Award

Published on by Research Hypothesis

Andrei Kozlov | Evolutionary Biology | Best Researcher Award

Prof Andrei Kozlov, Vavilov Institute of General Genetics RAS, Russia

Prof. Andrei Kozlov is the Chief of the Lab of Gene Neofunctionalization at the Vavilov Institute of General Genetics RAS and the Director of The Biomedical Center in St. Petersburg, Russia. He also heads the Kozlov Laboratory of Theoretical Biology at Peter the Great St. Petersburg Polytechnic University. Born on May 22, 1950, in St. Petersburg, he earned his M.Sci. in Biochemistry from Leningrad State University and his Ph.D. from the Petrov Research Institute of Oncology. With extensive research in molecular virology and oncology, he has significantly contributed to HIV and cancer research. Prof. Kozlov is married with three children. 📚🔬👨‍👩‍👧‍👦

Publication profile

scopus

Education

In 1972, I earned my M.Sci. in Biochemistry from the Chair of Biochemistry at Leningrad State University, Leningrad, Russia. 🧬 From 1972 to 1975, I pursued my Ph.D. at the Petrov Research Institute of Oncology in St. Petersburg, Russia, focusing on the biochemistry of nucleic acids in both normal and malignant tissues. My Ph.D. thesis was titled “A comparative study of low molecular weight nuclear RNAs in normal and tumor tissues.” 📚 Between 1978 and 1979, I underwent postdoctoral research training in the Lab of Tumor Cell Biology under Dr. R. C. Gallo at the NCI, NIH, Bethesda, MD, USA, specializing in molecular oncovirology. 🔬

Experience

In 1981, I began my career as a Molecular Biology Lecturer at the prestigious Boarding School №45 for especially talented children, attached to St. Petersburg State University. From 1983 to 1987, I lectured on the Biochemistry of nucleic acids at the university’s Department of Biochemistry. I founded and served as Deputy Director of the MPH Program at St. Petersburg State University from 2005 to 2012, where I also lectured on HIV/AIDS Epidemiology & Prevention. Since 2012, I’ve been the Founder and Chief of the St. Petersburg Seminar on Molecular and Evolutionary Biology. Between 2018 and 2019, I was a Professor in the Department of Medical Physics at Peter the Great St. Petersburg Polytechnic University, and since 2019, I have served as a High School Professor at the Institute of Biomedical Systems and Biotechnology. 🌟📚

Honors

From 1992 to 2010, a Fellowship at the International Agency for Research on Cancer (IARC) was the foundation for many notable achievements. During this time, the annual international conference “AIDS, Cancer and Public Health” was established, and 19 conferences were chaired. Notable positions included advisory roles to the Russian parliament on HIV legislation (1994-1995), coordination of the Russian HIV Vaccine Project (1998-2002), and serving on various advisory boards. Numerous awards were received, such as the Russian National Chumakov Award (1999) and the Vernadsky Award (2005). The Vavilov Prize (2020) recognized contributions to cancer and HIV research. 🧬🏅🌍

Research focus

It seems you’re interested in the research focus of A.P. Kozlov. Based on the list of publications provided, Kozlov’s research primarily revolves around the evolutionary and developmental biology (evo-devo) of gene expression, the role of tumors in evolution, and the relationship between normal and tumor-like organs. Kozlov’s work integrates aspects of molecular evolution, gene expression patterns in cancer, and the emergence of novel cell types during evolution. Notably, Kozlov explores the theory of “carcino-evo-devo,” which posits a significant evolutionary role for hereditary tumors. This interdisciplinary approach spans genomics, oncology, and evolutionary biology, shedding light on the complexity of developmental processes and cancer evolution. 🧬🔬🦠📊

Publication top notes

Diagrams Describing the Evolution of Gene Expression, the Emergence of Novel Cell Types During Evolution, and Evo-devo

Carcino-Evo-Devo, A Theory of the Evolutionary Role of Hereditary Tumors

The Theory of Carcino-Evo-Devo and Its Non-Trivial Predictions

Mammalian tumor-like organs. 2. Mammalian adipose has many tumor features and obesity is a tumor-like process

Mammalian tumor-like organs. 1. The role of tumor-like normal organs and atypical tumor organs in the evolution of development

Biological Computation and Compatibility Search in the Possibility Space as the Mechanism of Complexity Increase During Progressive Evolution

Erratum: Evolutionarily novel genes are expressed in transgenic fish tumors and their orthologs are involved in development of progressive traits in humans (Infectious Agents and Cancer (2019) 14 (46) DOI: 10.1186/s13027-019-0262-5)

Evolutionarily novel genes are expressed in transgenic fish tumors and their orthologs are involved in development of progressive traits in humans

Oncogenes, tumor suppressor and differentiation genes represent the oldest human gene classes and evolve concurrently

The increase of the magnitude of spontaneous viral blips in some participants of phase II clinical trial of therapeutic optimized HIV DNA vaccine candidate